NEW YORK (GenomeWeb News) – Molecular Diagnostics firm GenomeDx said today it has entered into agreements to provide laboratory testing as a participating provider with three preferred provider networks.
The PPOs are Stratose, Three Rivers Provider network, and Fortified Provider Network. The deals expand the number of covered lives with access to GenomeDx's Decipher prostate cancer classifier test by 62.6 million, the San Diego-based firm said.
The Decipher test analyzes whole genomes to profile RNA expression signatures. It measures the aggressiveness of prostate cancer in patients who have had a prostatectomy and classifies a patient's risk of disease progression, metastasis, and prostate-related death after a prostatectomy.
"We are focusing on providing access to patients who can benefit from the Decipher test, which offers physicians and their patients actionable information from which to make informed decisions about the course of treatment after prostate surgery," GenomeDx CEO Doug Dolginow said in a statement. "These agreements represent just the beginning of our efforts to engage payors."
GenomeDx closed a Series B financing round in late September for an undisclosed amount.